We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 20, 2021

ARTO System Treatment of Functional Mitral Regurgitation: 2-Year Outcomes

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
Two-Year Outcomes From the MitrAl ValvE RepaIr Clinical (MAVERIC) Trial: A Novel Percutaneous Treatment of Functional Mitral Regurgitation
Eur. J. Heart Fail 2021 Aug 06;[EPub Ahead of Print], T Patterson, J Gregson, A Erglis, J Joseph, R Rajani, K Wilson, B Prendergast, S Worthley, D Hildick-Smith, T Rafter, A Whelan, F De Marco, M Horrigan, SR Redwood

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading